gdc
PSSGuide_2020
Kidney Cancer

Drugs for Kidney (Renal-Cell) Cancer

Here are the drugs and financial support services available to patients receiving treatment for Kidney (Renal-Cell) Cancer.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Afinitor for free until a prescription drug coverage becomes available to them.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 120 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

Bavencio is a PD-L1 inhibitor used, in combination with axitinib, for the first-line treatment of patients with advanced renal-cell carcinoma (kidney cancer).

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $10 copay for Bavencio at participating medical facilities and pharmacies and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Cabometyx (cabozantinib)

Drug company: Exelixis
844-900-3273

Cabometyx is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Exelixis Access Services offers 4 financial assistance programs for patients using Cabometyx:

EASE Co-pay Program

Patients with private insurance who are eligible for this program will pay $0 per month for Cabometyx, for a maximum benefit of $25,000 per year.

EASE Quick Start Program

Eligible patients who experience a delay of more than 5 days in the processing or approval of their prescription can receive a 15-day supply of Cabometyx with refills as needed (up to 60 days).

EASE Patient Assistance Program

This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.

Dose Exchange Program

Patients who require a dose reduction to their therapy with Cabometyx can receive a free, 1-time supply of Cabometyx tablets in the new dose strength.

Inlyta (axitinib)

Drug company: Pfizer
877-744-5675

Inlyta is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 2 financial assistance programs for patients using Inlyta:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Inlyta is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Inlyta for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Inlyta for free.

Keytruda (pembrolizumab)

Drug company: Merck
877-744-5675

Keytruda is a PD-1 inhibitor used, in combination with axitinib, for the first-line treatment of patients with advanced renal-cell carcinoma (kidney cancer).

The Merck Access Program offers 2 financial assistance programs for patients using Keytruda:

Merck Co-Pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have a household income of $62,450 or less for individuals, $84,550 or less for a couple, or $128,750 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used, in combination with everolimus, for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma (kidney cancer).

Amgen offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Mvasi for free.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Bayer offers 2 financial assistance programs for patients using Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay $0 copay for Nexavar, and the program pays up to $25,000 annually, with no monthly maximum.

REACH Patient Assistance Program

Uninsured or underinsured patients can contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer). Opdivo is also used, in combination with Yervoy, for the treatment of patients with intermediate- or poor-risk advanced renal-cell carcinoma that was not previously treated.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Sutent (sunitinib malate) Capsules

Drug company: Pfizer
877-744-5675

Sutent is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Sutent for free.

Torisel (temsirolimus)

Drug company: Pfizer
877-744-5675

Torisel is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Pfizer Oncology Together offers 1 financial assistance program for patients using Torisel:

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Torisel for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Torisel for free.

Votrient (pazopanib)

Drug company: Novartis
800-245-5356

Votrient is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Votrient:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance for Votrient. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Votrient for free until a prescription drug coverage becomes available to them.

Yervoy (ipilimumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Yervoy is a human CTLA-4 inhibitor used, in combination with Opdivo, for the treatment of patients with intermediate- or poor-risk advanced renal-cell carcinoma that was not previously treated.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay $25 copay, and BMS covers the remaining amount, up to $25,000 annually per product (or $50,000 annually for 2 BMS products administered in combination).

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Table. Drugs Prescribed for Kidney (Renal-Cell) Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services









    Drug name (generic name)
  • Torisel (temsirolimus)
  • Drug company
  • Pfizer
  • Indication
  • Advanced renal-cell carcinoma
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675



Last modified: April 13, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country